
WVE Stock Forecast & Price Target
WVE Analyst Ratings
Bulls say
Wave Life Sciences is positioned to potentially transform human health through their innovative RNA medicines platform, PRISM, which combines multiple modalities, chemistry innovation, and deep insights into human genetics. Positive mid-2026 FDA accelerated approval feedback for their potential blockbuster drug, WVE-006, and the data expected at EASL in second quarter of 2026 could validate its regulatory strategy. The company's high potential for success is reflected in their strong pipeline and partnerships with other major biotech companies.
Bears say
Wave Life Sciences is facing strong competitive pressures, as new biomarker data from Sanofi establishes a higher reference point for total AAT levels and functional AAT trough in the lung disease segment. This, combined with a regulatory lead held by a competitor and potential uncertainties around the FDA's biomarker composite and threshold, raises questions about the company's commercial differentiation and its ability to secure approval and market share. There is also a high clinical risk associated with the early-stage nature of the company's pipeline, as well as other standard biotech industry risks.
This aggregate rating is based on analysts' research of Wave Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
WVE Analyst Forecast & Price Prediction
Start investing in WVE
Order type
Buy in
Order amount
Est. shares
0 shares